Atara Biotherapeutics Inc (ATRA) to Post FY2022 Earnings of ($1.74) Per Share, William Blair Forecasts
Atara Biotherapeutics Inc (NASDAQ:ATRA) – Stock analysts at William Blair issued their FY2022 earnings per share estimates for Atara Biotherapeutics in a report issued on Tuesday. William Blair analyst M. Phipps expects that the biotechnology company will earn ($1.74) per share for the year.
Other analysts also recently issued reports about the company. Canaccord Genuity reissued a “buy” rating on shares of Atara Biotherapeutics in a research note on Friday, December 29th. BidaskClub raised Atara Biotherapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, January 11th. Zacks Investment Research raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Thursday. ValuEngine raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Friday, December 29th. Finally, Citigroup raised Atara Biotherapeutics from a “sell” rating to a “neutral” rating and set a $18.00 price objective for the company in a research note on Wednesday, January 3rd. One investment analyst has rated the stock with a sell rating, three have given a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $30.60.
In related news, CEO Isaac E. Ciechanover sold 20,000 shares of the stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $46.80, for a total transaction of $936,000.00. Following the completion of the sale, the chief executive officer now directly owns 808,675 shares of the company’s stock, valued at $37,845,990. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Heather D. Turner sold 12,214 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $38.01, for a total value of $464,254.14. Following the sale, the executive vice president now directly owns 77,112 shares of the company’s stock, valued at $2,931,027.12. The disclosure for this sale can be found here. Insiders have sold 290,914 shares of company stock valued at $7,969,587 over the last ninety days. 16.20% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC bought a new position in Atara Biotherapeutics during the third quarter valued at $142,000. Russell Investments Group Ltd. bought a new position in Atara Biotherapeutics during the third quarter valued at $170,000. Voya Investment Management LLC grew its holdings in Atara Biotherapeutics by 16.2% during the second quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock valued at $165,000 after purchasing an additional 1,651 shares during the period. MetLife Investment Advisors LLC bought a new position in Atara Biotherapeutics during the fourth quarter valued at $217,000. Finally, The Manufacturers Life Insurance Company grew its holdings in Atara Biotherapeutics by 7.2% during the second quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock valued at $285,000 after purchasing an additional 1,369 shares during the period. 69.58% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This story was posted by Watch List News and is owned by of Watch List News. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.watchlistnews.com/atara-biotherapeutics-inc-atra-to-post-fy2022-earnings-of-1-74-per-share-william-blair-forecasts/1870925.html.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.